These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1946358)

  • 21. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys.
    Voss G; Letvin NL
    J Virol; 1996 Oct; 70(10):7335-40. PubMed ID: 8794394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys.
    Egan MA; Kuroda MJ; Voss G; Schmitz JE; Charini WA; Lord CI; Forman MA; Letvin NL
    J Virol; 1999 Jul; 73(7):5466-72. PubMed ID: 10364294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24.
    Nishino Y; Kameoka M; Okada Y; Zhong Q; Kimura T; Azuma I; Ikuta K
    Vaccine; 1994 May; 12(6):485-91. PubMed ID: 7913566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop.
    Kameoka M; Nishino Y; Matsuo K; Ohara N; Kimura T; Yamazaki A; Yamada T; Ikuta K
    Vaccine; 1994 Feb; 12(2):153-8. PubMed ID: 8147098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.
    Takahashi H; Takeshita T; Morein B; Putney S; Germain RN; Berzofsky JA
    Nature; 1990 Apr; 344(6269):873-5. PubMed ID: 2184369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.
    Sedlik C; Dadaglio G; Saron MF; Deriaud E; Rojas M; Casal SI; Leclerc C
    J Virol; 2000 Jul; 74(13):5769-75. PubMed ID: 10846055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.
    Takahashi H; Nakagawa Y; Yokomuro K; Berzofsky JA
    Int Immunol; 1993 Aug; 5(8):849-57. PubMed ID: 8398980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
    Takahashi H; Cohen J; Hosmalin A; Cease KB; Houghten R; Cornette JL; DeLisi C; Moss B; Germain RN; Berzofsky JA
    Proc Natl Acad Sci U S A; 1988 May; 85(9):3105-9. PubMed ID: 2452443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
    Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
    J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.